112 related articles for article (PubMed ID: 1396050)
1. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
Ding DC
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of trimetrexate in combination with cisplatin.
Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
4. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
5. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
Campbell AB; Kalman SM; Jacobs C
Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
8. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
9. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
[TBL] [Abstract][Full Text] [Related]
11. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Hua XM; Ren XW; Liu FL; Liu Y; Zhang CJ; Li ZJ; Xu L; Liu JY; Liu YG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):621-5. PubMed ID: 15634526
[TBL] [Abstract][Full Text] [Related]
12. [Cisplatin nephrotoxicity: clinical observation and animal experiment].
Qiu XF; Li ZX
Zhonghua Fu Chan Ke Za Zhi; 1992 Jan; 27(1):35-7, 59. PubMed ID: 1505276
[TBL] [Abstract][Full Text] [Related]
13. [Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Wang QL
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):222-5. PubMed ID: 2612337
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
17. [Combination chemotherapy with Taxol and cisplatin for 57 patients with non-small cell lung cancer by intraartery and intravenous infusion].
Zhao Y; Wang SM; Zhang J
Ai Zheng; 2002 Dec; 21(12):1365-7. PubMed ID: 12520750
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
